Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion
Primary Purpose
Trigeminal Neuralgia
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Deep brain stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Trigeminal Neuralgia focused on measuring Multiple sclerosis, Deep brain stimulation
Eligibility Criteria
Inclusion Criteria:
- Adults of at least 18 years old
- Refractory trigeminal neuralgia (failure of at least 3 drugs and at least one surgical intervention)
- Demyelinating pontine lesion proved by MRI in contact with trigeminal nerve tract
Exclusion Criteria:
- Absolute contraindication to MRI
- Medical contraindication to the procedure
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Deep brain stimulation
Arm Description
Implantation of deep brain stimulation lead within the pontine demyelinating lesion
Outcomes
Primary Outcome Measures
Demonstrating the feasibility of the intervention by assessing protocol completion without deviation
Protocol completion defined by:
Lead implantation with success
Adjustment of stimulation parameters to minimize adverse effects
Minimal follow-up of 6 months after intervention
Secondary Outcome Measures
Lead implantation accuracy
Difference between target and actual lead position
Pain evolution
Evolution of pain severity after the intervention according to the modified Barrow Neurological Institute (mBNI) grading scale.
Complications
Complications arising from the intervention according to the Common Terminology Criteria for Adverse Events (CTCAE) grading scale.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05451251
Brief Title
Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion
Official Title
Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion: a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2022 (Anticipated)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
February 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Université de Sherbrooke
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
5. Study Description
Brief Summary
The aim of this study is to assess the feasibility of deep brain stimulation for refractory trigeminal neuralgia due to a pontine demyelinating lesion, as is usually seen in the context of multiple sclerosis.
These patients usually have severe intractable facial pain and current medical and surgical options generally fail to achieve long lasting pain relief.
Hoping to improve pain control in this population, the investigators of this trial propose a novel technique consisting of implanting a deep brain stimulation lead within the pontine lesion to modulate the generation of pain signals.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trigeminal Neuralgia
Keywords
Multiple sclerosis, Deep brain stimulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Deep brain stimulation
Arm Type
Experimental
Arm Description
Implantation of deep brain stimulation lead within the pontine demyelinating lesion
Intervention Type
Device
Intervention Name(s)
Deep brain stimulation
Intervention Description
Implantation of deep brain stimulation lead within the pontine demyelinating lesion
Primary Outcome Measure Information:
Title
Demonstrating the feasibility of the intervention by assessing protocol completion without deviation
Description
Protocol completion defined by:
Lead implantation with success
Adjustment of stimulation parameters to minimize adverse effects
Minimal follow-up of 6 months after intervention
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Lead implantation accuracy
Description
Difference between target and actual lead position
Time Frame
24 months
Title
Pain evolution
Description
Evolution of pain severity after the intervention according to the modified Barrow Neurological Institute (mBNI) grading scale.
Time Frame
24 months
Title
Complications
Description
Complications arising from the intervention according to the Common Terminology Criteria for Adverse Events (CTCAE) grading scale.
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults of at least 18 years old
Refractory trigeminal neuralgia (failure of at least 3 drugs and at least one surgical intervention)
Demyelinating pontine lesion proved by MRI in contact with trigeminal nerve tract
Exclusion Criteria:
Absolute contraindication to MRI
Medical contraindication to the procedure
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christian Iorio-Morin, MD
Phone
819-346-1110
Ext
16365
Email
Christian.Iorio-Morin@usherbrooke.ca
12. IPD Sharing Statement
Learn more about this trial
Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion
We'll reach out to this number within 24 hrs